ZA200304159B - An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues. - Google Patents
An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues. Download PDFInfo
- Publication number
- ZA200304159B ZA200304159B ZA200304159A ZA200304159A ZA200304159B ZA 200304159 B ZA200304159 B ZA 200304159B ZA 200304159 A ZA200304159 A ZA 200304159A ZA 200304159 A ZA200304159 A ZA 200304159A ZA 200304159 B ZA200304159 B ZA 200304159B
- Authority
- ZA
- South Africa
- Prior art keywords
- tissue
- agent
- group
- therapeutic
- target tissue
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 125
- 229940124597 therapeutic agent Drugs 0.000 title claims description 36
- 238000012384 transportation and delivery Methods 0.000 title claims description 29
- 210000001519 tissue Anatomy 0.000 claims description 141
- 239000003795 chemical substances by application Substances 0.000 claims description 93
- 229940079593 drug Drugs 0.000 claims description 88
- 238000000034 method Methods 0.000 claims description 75
- 238000007789 sealing Methods 0.000 claims description 74
- 210000000056 organ Anatomy 0.000 claims description 40
- 229920000642 polymer Polymers 0.000 claims description 25
- 230000001225 therapeutic effect Effects 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 18
- 239000000853 adhesive Substances 0.000 claims description 17
- 230000001070 adhesive effect Effects 0.000 claims description 17
- 230000007246 mechanism Effects 0.000 claims description 17
- 239000003623 enhancer Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 11
- 230000000069 prophylactic effect Effects 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 239000004633 polyglycolic acid Substances 0.000 claims description 7
- 229950008885 polyglycolic acid Drugs 0.000 claims description 7
- 239000004626 polylactic acid Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000002357 osmotic agent Substances 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 201000000582 Retinoblastoma Diseases 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000017 hydrogel Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000010412 perfusion Effects 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 230000002107 myocardial effect Effects 0.000 claims description 4
- 239000002745 poly(ortho ester) Substances 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- -1 polyethylene Polymers 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 229940014259 gelatin Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 230000001788 irregular Effects 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229960002900 methylcellulose Drugs 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 102000029816 Collagenase Human genes 0.000 claims description 2
- 108060005980 Collagenase Proteins 0.000 claims description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 2
- 239000003124 biologic agent Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229960005188 collagen Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 229940014041 hyaluronate Drugs 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000003504 photosensitizing agent Substances 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims 4
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920000573 polyethylene Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920005573 silicon-containing polymer Polymers 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 102000010911 Enzyme Precursors Human genes 0.000 claims 1
- 108010062466 Enzyme Precursors Proteins 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 230000003034 chemosensitisation Effects 0.000 claims 1
- 239000006114 chemosensitizer Substances 0.000 claims 1
- 229940126523 co-drug Drugs 0.000 claims 1
- 229960002424 collagenase Drugs 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 229960002086 dextran Drugs 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000013013 elastic material Substances 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 239000010410 layer Substances 0.000 description 36
- 210000003786 sclera Anatomy 0.000 description 33
- 210000001508 eye Anatomy 0.000 description 31
- 238000009792 diffusion process Methods 0.000 description 18
- 238000002513 implantation Methods 0.000 description 17
- 238000012377 drug delivery Methods 0.000 description 16
- 239000012790 adhesive layer Substances 0.000 description 15
- 239000012530 fluid Substances 0.000 description 13
- 239000007943 implant Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 239000003381 stabilizer Substances 0.000 description 13
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 210000004165 myocardium Anatomy 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 231100000331 toxic Toxicity 0.000 description 9
- 230000002588 toxic effect Effects 0.000 description 9
- 238000000576 coating method Methods 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000002459 sustained effect Effects 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 229920001296 polysiloxane Polymers 0.000 description 7
- 230000002035 prolonged effect Effects 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 210000003516 pericardium Anatomy 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 210000003161 choroid Anatomy 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 239000004621 biodegradable polymer Substances 0.000 description 4
- 229920002988 biodegradable polymer Polymers 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012867 bioactive agent Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 3
- 229960005156 digoxin Drugs 0.000 description 3
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000009958 sewing Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001688 coating polymer Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000011521 systemic chemotherapy Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 210000001760 tenon capsule Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000006444 vascular growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 208000024304 Choroidal Effusions Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 241000278713 Theora Species 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000026563 adrenal gland neuroblastoma Diseases 0.000 description 1
- 201000010420 adrenal neuroblastoma Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003306 cell dissemination Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000009791 fibrotic reaction Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- RPQUGMLCZLGZTG-UHFFFAOYSA-N octyl cyanoacrylate Chemical compound CCCCCCCCOC(=O)C(=C)C#N RPQUGMLCZLGZTG-UHFFFAOYSA-N 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 238000001721 transfer moulding Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31595201P | 2001-08-29 | 2001-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200304159B true ZA200304159B (en) | 2004-08-30 |
Family
ID=23226807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200304159A ZA200304159B (en) | 2001-08-29 | 2003-05-28 | An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues. |
Country Status (12)
Country | Link |
---|---|
US (1) | US7195774B2 (de) |
EP (1) | EP1420716B1 (de) |
JP (2) | JP2005501602A (de) |
CN (1) | CN1578647B (de) |
AU (1) | AU2002324811B2 (de) |
BR (1) | BR0205990A (de) |
CA (1) | CA2456025C (de) |
ES (1) | ES2393101T3 (de) |
PT (1) | PT1420716E (de) |
RU (1) | RU2311892C2 (de) |
WO (1) | WO2003020172A1 (de) |
ZA (1) | ZA200304159B (de) |
Families Citing this family (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2358296A1 (en) * | 1999-01-05 | 2000-07-13 | Anthony P. Adamis | Targeted transscleral controlled release drug delivery to the retina and choroid |
US7943162B2 (en) * | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
FR2822049B1 (fr) * | 2001-03-13 | 2003-08-01 | Dbv Medica 1 | Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation |
US7635488B2 (en) * | 2001-03-13 | 2009-12-22 | Dbv Technologies | Patches and uses thereof |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
DE60239868D1 (de) | 2001-06-12 | 2011-06-09 | Univ Johns Hopkins Med | Reservoirvorrichtung für die intraokulare arzneimittelabgabe |
US7195774B2 (en) | 2001-08-29 | 2007-03-27 | Carvalho Ricardo Azevedo Ponte | Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
US7749528B2 (en) | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
CA2478772C (en) | 2002-03-11 | 2011-01-18 | Alcon, Inc. | Implantable drug delivery system |
WO2003092665A2 (en) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
CA2689424A1 (en) * | 2002-09-29 | 2004-04-08 | Surmodics, Inc. | Methods for treatment and/or prevention of retinal disease |
WO2004073551A2 (en) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
US7862546B2 (en) * | 2003-06-16 | 2011-01-04 | Ethicon Endo-Surgery, Inc. | Subcutaneous self attaching injection port with integral moveable retention members |
US8715243B2 (en) * | 2003-06-16 | 2014-05-06 | Ethicon Endo-Surgery, Inc. | Injection port applier with downward force actuation |
US7850660B2 (en) | 2003-12-19 | 2010-12-14 | Ethicon Endo-Surgery, Inc. | Implantable medical device with simultaneous attachment mechanism and method |
WO2005020907A2 (en) * | 2003-08-26 | 2005-03-10 | Vista Scientific | Ocular drug delivery device |
US8257963B2 (en) * | 2007-06-01 | 2012-09-04 | Depuy Mitek, Inc. | Chondrocyte container and method of use |
US7897384B2 (en) * | 2003-09-08 | 2011-03-01 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
US7927599B2 (en) | 2003-09-08 | 2011-04-19 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
JP4722850B2 (ja) | 2003-09-15 | 2011-07-13 | アラーガン、インコーポレイテッド | 植込み式デバイス締付けシステムおよび使用方法 |
US7291125B2 (en) * | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US8162897B2 (en) * | 2003-12-19 | 2012-04-24 | Ethicon Endo-Surgery, Inc. | Audible and tactile feedback |
US20050137538A1 (en) * | 2003-12-22 | 2005-06-23 | Bausch & Lomb Incorporated | Drug delivery device |
NZ586427A (en) * | 2004-01-23 | 2010-12-24 | Allergan Sales Llc | Deployment of fasteners for tissue implantable access port |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US20050245905A1 (en) * | 2004-04-30 | 2005-11-03 | Schmidt Steven P | Local drug-delivery system |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
WO2006002366A2 (en) * | 2004-06-24 | 2006-01-05 | Surmodics, Inc. | Biodegradable ocular devices, methods and systems |
US7922702B2 (en) | 2004-07-02 | 2011-04-12 | Qlt Inc. | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device |
US20060110428A1 (en) * | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
WO2006039459A1 (en) * | 2004-09-30 | 2006-04-13 | Bausch & Lomb Incorporated | Capsule for encasing tablets for surgical insertion into the human body |
US20060163111A1 (en) * | 2004-12-23 | 2006-07-27 | Baril Daniel J | Device holder apparatus |
CA2601864A1 (en) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease |
US7651483B2 (en) * | 2005-06-24 | 2010-01-26 | Ethicon Endo-Surgery, Inc. | Injection port |
US7918844B2 (en) | 2005-06-24 | 2011-04-05 | Ethicon Endo-Surgery, Inc. | Applier for implantable medical device |
US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
WO2007052730A1 (ja) * | 2005-10-31 | 2007-05-10 | Nagasaki University | 硝子体内注射用固定具 |
US20090306687A1 (en) * | 2005-10-31 | 2009-12-10 | Life Spring Biotech Co., Ltd. | Scleral buckling band and method for making the same |
US20080293691A1 (en) | 2005-11-29 | 2008-11-27 | Smithkline Beecham Corporation | Treatment Method |
PL2526910T3 (pl) * | 2006-01-17 | 2016-01-29 | Novartis Ag | Urządzenie do leczenia jaskry |
WO2007084582A2 (en) * | 2006-01-17 | 2007-07-26 | Forsight Labs, Llc | Drug delivery treatment device |
ES2493921T3 (es) * | 2006-03-14 | 2014-09-12 | University Of Southern California | Dispositivo MEMS para la administración de agentes terapéuticos |
US8216603B2 (en) * | 2006-05-04 | 2012-07-10 | Herbert Edward Kaufman | Method, device, and system for delivery of therapeutic agents to the eye |
US20080287915A1 (en) * | 2007-05-15 | 2008-11-20 | Boston Foundation For Sight | Tissue engineering system with scleral lens |
US20080286338A1 (en) * | 2007-05-15 | 2008-11-20 | Boston Foundation For Sight | Drug delivery system with scleral lens |
US20080286337A1 (en) * | 2007-05-15 | 2008-11-20 | Boston Foundation For Sight | Method of treating a disease in an eye using a scleral lens |
US8672870B2 (en) * | 2007-07-17 | 2014-03-18 | Transcend Medical, Inc. | Ocular implant with hydrogel expansion capabilities |
DE102007044116A1 (de) * | 2007-09-16 | 2009-04-02 | Leica Biosystems Nussloch Gmbh | Gewebeinfiltrationsvorrichtung |
US8480638B2 (en) * | 2007-10-04 | 2013-07-09 | Aciont, Inc. | Intraocular iontophoretic device and associated methods |
CA2705859A1 (en) * | 2007-10-15 | 2009-04-23 | John P. Stokes | Convergent well irradiating plaque for choroidal melanoma |
EP2219666A4 (de) * | 2007-11-15 | 2011-05-25 | Univ North Carolina | Prostata-säure-phosphatase zur behandlung von schmerzen |
FR2924349B1 (fr) | 2007-12-03 | 2010-01-01 | Dbv Tech | Methode de desensibilitation aux allergenes |
FR2924350B1 (fr) * | 2007-12-03 | 2010-08-13 | Dbv Tech | Procede et compositions pour la vaccination par voie cutanee |
ES2425769T5 (es) * | 2007-12-20 | 2017-07-28 | University Of Southern California | Aparato para la administración de agentes terapéuticos |
EP2240220B1 (de) * | 2008-01-03 | 2016-04-13 | University Of Southern California | Implantierbare wirkstofffreisetzungsvorrichtungen sowie geräte zum auffüllen der vorrichtungen |
FR2926466B1 (fr) * | 2008-01-23 | 2010-11-12 | Dbv Tech | Procede de fabrication de patchs par electrospray |
GB2470327B (en) * | 2008-03-07 | 2012-03-21 | Milwaukee Electric Tool Corp | Visual inspection device |
EP2471572A3 (de) * | 2008-04-17 | 2012-10-17 | Allergan, Inc. | Implantierbare Injektionsportvorrichtung |
US9023063B2 (en) | 2008-04-17 | 2015-05-05 | Apollo Endosurgery, Inc. | Implantable access port device having a safety cap |
US8231608B2 (en) | 2008-05-08 | 2012-07-31 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
EP2320972B1 (de) | 2008-05-08 | 2020-07-01 | MiniPumps, LLC | Implantierbare arzneiabgabevorrichtungen |
EP2320989B1 (de) * | 2008-05-08 | 2015-03-11 | MiniPumps, LLC | Implantierbare pumpen und kanülen dafür |
US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US10588855B2 (en) | 2008-05-12 | 2020-03-17 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
CN102026599A (zh) * | 2008-05-12 | 2011-04-20 | 犹他大学研究基金会 | 眼内药物递送装置及相关方法 |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
WO2010027851A1 (en) * | 2008-08-26 | 2010-03-11 | Massachusetts Institute Of Technology | Devices and systems for local delivery of inotropic agents to the epicardium |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
CN102497871B (zh) | 2008-11-14 | 2014-10-15 | 希斯托金公司 | 用于癌症治疗的胞外基质组合物 |
US8377122B2 (en) | 2009-01-28 | 2013-02-19 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
CA3045436A1 (en) | 2009-01-29 | 2010-08-05 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
EP4108216A1 (de) | 2009-06-03 | 2022-12-28 | Forsight Vision5, Inc. | Wirkstofffreisetzung im vorderen augensegment |
EP2467797B1 (de) | 2009-08-18 | 2017-07-19 | MiniPumps, LLC | Elektrolytische arzneimittelverabreichungspumpe mit adaptiver steuerung |
US8506532B2 (en) * | 2009-08-26 | 2013-08-13 | Allergan, Inc. | System including access port and applicator tool |
US8708979B2 (en) | 2009-08-26 | 2014-04-29 | Apollo Endosurgery, Inc. | Implantable coupling device |
US8715158B2 (en) * | 2009-08-26 | 2014-05-06 | Apollo Endosurgery, Inc. | Implantable bottom exit port |
WO2011031299A1 (en) * | 2009-08-28 | 2011-03-17 | Mount Sinai School Of Medicine Of New York University | Intrapericardial injections |
WO2011039648A1 (en) | 2009-09-30 | 2011-04-07 | Glaxo Wellcome Manufacturing Pte Ltd. | Methods of administration and treatment |
US20110105990A1 (en) * | 2009-11-04 | 2011-05-05 | Silvestrini Thomas A | Zonal drug delivery device and method |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US20110196195A1 (en) * | 2010-02-05 | 2011-08-11 | Allergan, Inc. | Implantable subcutaneous access port |
US8882728B2 (en) * | 2010-02-10 | 2014-11-11 | Apollo Endosurgery, Inc. | Implantable injection port |
US20110270025A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Remotely powered remotely adjustable gastric band system |
US8992415B2 (en) | 2010-04-30 | 2015-03-31 | Apollo Endosurgery, Inc. | Implantable device to protect tubing from puncture |
US20110270021A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Electronically enhanced access port for a fluid filled implant |
JP2013526572A (ja) | 2010-05-17 | 2013-06-24 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | 眼治療薬の送達のための薬物送達装置 |
US8939948B2 (en) | 2010-06-01 | 2015-01-27 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US9033911B2 (en) | 2010-08-05 | 2015-05-19 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
JP5907966B2 (ja) | 2010-08-05 | 2016-04-26 | フォーサイト・ビジョン フォー・インコーポレーテッド | 埋め込み型治療デバイス |
EP2603580B1 (de) | 2010-08-13 | 2017-04-12 | Wake Forest University Health Sciences | Verfahren zur in-vitro-herstellung eines gewebegezüchteten muskelreparatur-konstrukts zur in-vivo-implantation |
US20120041258A1 (en) | 2010-08-16 | 2012-02-16 | Allergan, Inc. | Implantable access port system |
US20120065460A1 (en) | 2010-09-14 | 2012-03-15 | Greg Nitka | Implantable access port system |
US20120083767A1 (en) | 2010-10-01 | 2012-04-05 | The Johns Hopkins University | Implantable bioreactor for delivery of paracrine factors |
EP2640360A2 (de) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutische wirkstoffformulierungen für implantierte vorrichtungen |
US10286146B2 (en) | 2011-03-14 | 2019-05-14 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US9919099B2 (en) | 2011-03-14 | 2018-03-20 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US9603997B2 (en) | 2011-03-14 | 2017-03-28 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
US8821373B2 (en) | 2011-05-10 | 2014-09-02 | Apollo Endosurgery, Inc. | Directionless (orientation independent) needle injection port |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
WO2013003620A2 (en) | 2011-06-28 | 2013-01-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
US8801597B2 (en) | 2011-08-25 | 2014-08-12 | Apollo Endosurgery, Inc. | Implantable access port with mesh attachment rivets |
WO2013033791A1 (en) * | 2011-09-09 | 2013-03-14 | Endoluminal Sciences Pty Ltd | Means for controlled sealing of endovascular devices |
US9102105B2 (en) | 2011-09-13 | 2015-08-11 | Vista Scientific Llc | Method for forming an ocular drug delivery device |
EP3903733A1 (de) | 2011-09-16 | 2021-11-03 | ForSight Vision4, Inc. | Flüssigkeitsaustauschvorrichtung |
US9199069B2 (en) | 2011-10-20 | 2015-12-01 | Apollo Endosurgery, Inc. | Implantable injection port |
US8858421B2 (en) | 2011-11-15 | 2014-10-14 | Apollo Endosurgery, Inc. | Interior needle stick guard stems for tubes |
US9089395B2 (en) | 2011-11-16 | 2015-07-28 | Appolo Endosurgery, Inc. | Pre-loaded septum for use with an access port |
IN2014DN06472A (de) * | 2012-01-27 | 2015-06-12 | Ecole Polytech | |
WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
WO2014043698A2 (en) | 2012-09-17 | 2014-03-20 | Transcend Medical, Inc. | Expanding ocular implant devices and methods |
US20140100530A1 (en) | 2012-10-05 | 2014-04-10 | Miguel A. Linares | Attachable uterine device with integrated and time release medicinal administering component and insertion tool for implanting such a device |
PT2911623T (pt) | 2012-10-26 | 2019-11-21 | Forsight Vision5 Inc | Sistema oftálmico para libertação prolongada de fármaco no olho |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
EP2968113B8 (de) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systeme zur verzögerten intraokularen abgabe schwerlöslicher verbindungen aus einem implantat mit einem portabgabesystem |
CA2907681C (en) | 2013-03-28 | 2022-11-22 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
US10098836B2 (en) | 2013-05-02 | 2018-10-16 | Retina Foundation Of The Southwest | Method for forming a molded two-layer ocular implant |
JP6655610B2 (ja) | 2014-05-29 | 2020-02-26 | グローコス コーポレーション | 制御された薬物送達機能を備えるインプラント及びそれを使用する方法 |
RU2695563C2 (ru) | 2014-07-15 | 2019-07-24 | Форсайт Вижн4, Инк. | Способ и устройство для доставки глазного имплантата |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
CN111214701A (zh) * | 2014-08-19 | 2020-06-02 | 加利福尼亚大学董事会 | 用于局部药物递送的植入物及其使用方法 |
CN114587774A (zh) | 2014-11-10 | 2022-06-07 | 弗赛特影像4股份有限公司 | 治疗眼睛的系统 |
US9615927B2 (en) * | 2015-03-31 | 2017-04-11 | Depuy Ireland Unlimited Company | Orthopaedic surgical instrument system and method for protecting a femoral stem taper |
US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
US10010502B2 (en) | 2015-05-19 | 2018-07-03 | Amorphex Therapeutics Llc | Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation |
CN106620893B (zh) * | 2015-07-23 | 2021-07-30 | 爱博诺德(北京)医疗科技股份有限公司 | 用于眼部疾病光治疗的材料 |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
KR20180084104A (ko) | 2015-11-20 | 2018-07-24 | 포사이트 비젼4, 인크. | 연장 방출 약물 전달 장치를 위한 다공성 구조물 |
CN107007891B (zh) * | 2016-01-27 | 2023-09-19 | 上海交通大学医学院附属第九人民医院 | 一种密闭的带有组织再生室的组织器官的再生装置 |
JP6781973B2 (ja) * | 2016-01-29 | 2020-11-11 | 学校法人東京女子医科大学 | 腎臓病進行抑制細胞シート組成物、その製造方法、及び、それを用いた腎臓病進行抑制方法 |
CN105997338B (zh) * | 2016-03-09 | 2019-04-26 | 泰山医学院 | 经玻璃体纳米材料给药系统 |
AR108177A1 (es) | 2016-04-05 | 2018-07-25 | Forsight Vision4 Inc | Dispositivos de suministro de fármacos oculares implantables |
JP7003110B2 (ja) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | 生体吸収性眼球薬物送達デバイス |
WO2018064578A1 (en) | 2016-09-30 | 2018-04-05 | Lynthera Corporation | High-precision drug delivery by dual-domain ocular device |
BR112020010053A2 (pt) | 2017-11-21 | 2020-11-03 | Forsight Vision4, Inc. | aparelho para troca de fluido para sistema de liberação de porta expansível e métodos de uso do mesmo |
WO2019195860A2 (en) | 2018-04-04 | 2019-10-10 | Vdyne, Llc | Devices and methods for anchoring transcatheter heart valve |
CN108815687B (zh) * | 2018-04-27 | 2020-07-28 | 河南中医药大学 | 一种食管癌化疗装置 |
EP3801378A4 (de) | 2018-05-24 | 2022-02-23 | Celanese EVA Performance Polymers LLC | Implantierbare vorrichtung zur verzögerten freisetzung einer makromolekularen wirkstoffverbindung |
CN111971026A (zh) | 2018-05-24 | 2020-11-20 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
CN108785791B (zh) * | 2018-06-08 | 2020-12-18 | 谢博宇 | 能够阻止血栓形成以及阻止继发感染的双腔静脉输液港 |
US11071627B2 (en) | 2018-10-18 | 2021-07-27 | Vdyne, Inc. | Orthogonally delivered transcatheter heart valve frame for valve in valve prosthesis |
US10321995B1 (en) | 2018-09-20 | 2019-06-18 | Vdyne, Llc | Orthogonally delivered transcatheter heart valve replacement |
US10595994B1 (en) | 2018-09-20 | 2020-03-24 | Vdyne, Llc | Side-delivered transcatheter heart valve replacement |
US11278437B2 (en) | 2018-12-08 | 2022-03-22 | Vdyne, Inc. | Compression capable annular frames for side delivery of transcatheter heart valve replacement |
US11344413B2 (en) | 2018-09-20 | 2022-05-31 | Vdyne, Inc. | Transcatheter deliverable prosthetic heart valves and methods of delivery |
US11109969B2 (en) | 2018-10-22 | 2021-09-07 | Vdyne, Inc. | Guidewire delivery of transcatheter heart valve |
US11253359B2 (en) | 2018-12-20 | 2022-02-22 | Vdyne, Inc. | Proximal tab for side-delivered transcatheter heart valves and methods of delivery |
US11273032B2 (en) | 2019-01-26 | 2022-03-15 | Vdyne, Inc. | Collapsible inner flow control component for side-deliverable transcatheter heart valve prosthesis |
US11185409B2 (en) | 2019-01-26 | 2021-11-30 | Vdyne, Inc. | Collapsible inner flow control component for side-delivered transcatheter heart valve prosthesis |
CA3132162A1 (en) | 2019-03-05 | 2020-09-10 | Vdyne, Inc. | Tricuspid regurgitation control devices for orthogonal transcatheter heart valve prosthesis |
US11076956B2 (en) | 2019-03-14 | 2021-08-03 | Vdyne, Inc. | Proximal, distal, and anterior anchoring tabs for side-delivered transcatheter mitral valve prosthesis |
US11173027B2 (en) | 2019-03-14 | 2021-11-16 | Vdyne, Inc. | Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same |
CN109907861B (zh) * | 2019-04-22 | 2021-03-02 | 清华大学深圳研究生院 | 一种多功能性角膜植片 |
EP3965701A4 (de) | 2019-05-04 | 2023-02-15 | Vdyne, Inc. | Cinchvorrichtung und verfahren zum einsatz einer seitlich freigesetzten herzklappenprothese in einem nativen ring |
US20220249700A1 (en) * | 2019-05-13 | 2022-08-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Polymer-based implant for retinal therapy and methods of making and using the same |
AU2020334080A1 (en) | 2019-08-20 | 2022-03-24 | Vdyne, Inc. | Delivery and retrieval devices and methods for side-deliverable transcatheter prosthetic valves |
CN114630665A (zh) | 2019-08-26 | 2022-06-14 | 维迪内股份有限公司 | 可侧面输送的经导管假体瓣膜及其输送和锚定方法 |
US11234813B2 (en) | 2020-01-17 | 2022-02-01 | Vdyne, Inc. | Ventricular stability elements for side-deliverable prosthetic heart valves and methods of delivery |
CN113616855A (zh) * | 2021-08-05 | 2021-11-09 | 苏州大学 | 一种储药植入体及制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2071223A5 (en) * | 1969-12-28 | 1971-09-17 | Rosen Hyman | Contact lens - for medicament application |
US4144317A (en) * | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4309776A (en) | 1980-05-13 | 1982-01-12 | Ramon Berguer | Intravascular implantation device and method of using the same |
US4768523A (en) * | 1981-04-29 | 1988-09-06 | Lifecore Biomedical, Inc. | Hydrogel adhesive |
US4378016A (en) | 1981-07-15 | 1983-03-29 | Biotek, Inc. | Artificial endocrine gland containing hormone-producing cells |
US4479796A (en) | 1982-11-15 | 1984-10-30 | Medtronic, Inc. | Self-regenerating drug administration device |
US5122127A (en) * | 1985-05-01 | 1992-06-16 | University Of Utah | Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues |
US4549529A (en) * | 1985-10-11 | 1985-10-29 | White Thomas C | Myopia alleviation prosthesis |
US4788971A (en) * | 1987-07-13 | 1988-12-06 | Hill Top Research, Inc. | Patch system for use on the skin |
US5182111A (en) | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
US4978338A (en) * | 1988-04-21 | 1990-12-18 | Therex Corp. | Implantable infusion apparatus |
US5292362A (en) * | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5411550A (en) * | 1991-09-16 | 1995-05-02 | Atrium Medical Corporation | Implantable prosthetic device for the delivery of a bioactive material |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5445616A (en) * | 1994-04-29 | 1995-08-29 | Medtronic, Inc. | Medication delivery device and method of construction |
CA2204789C (en) | 1994-11-10 | 2002-11-12 | Paul Ashton | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body |
US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5558630A (en) * | 1994-12-30 | 1996-09-24 | Fisher; Bret L. | Intrascleral implant and method for the regulation of intraocular pressure |
US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5980497A (en) * | 1996-03-15 | 1999-11-09 | Yavitz; Edward Q. | Membrane shield for eyes |
FR2761075B1 (fr) * | 1997-03-24 | 1999-06-11 | Seguin Marie Christine | Nouveaux composes a base de silicium biologiquement actifs et leurs applications therapeutiques |
EP0991404A1 (de) * | 1997-06-24 | 2000-04-12 | Schering-Plough Healthcare Products, Inc. | Vorrichtung zur verabreichung von dermatologische wirkstoffe |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US7008396B1 (en) * | 1999-09-03 | 2006-03-07 | Restorvision, Inc. | Ophthalmic device and method of manufacture and use |
ES2231257T3 (es) | 1999-10-21 | 2005-05-16 | Alcon Inc. | Dispositivo para la administracion de farmacos. |
US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
US6726920B1 (en) | 2000-09-22 | 2004-04-27 | Durect Corporation | Implantable drug delivery patch |
US7181287B2 (en) * | 2001-02-13 | 2007-02-20 | Second Sight Medical Products, Inc. | Implantable drug delivery device |
US7563255B2 (en) | 2001-05-03 | 2009-07-21 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
DE60217679T2 (de) * | 2001-07-23 | 2007-10-25 | Alcon Inc. | Vorrichtung zur freisetzung eines ophthalmischen arzneimittels |
US8267995B2 (en) * | 2001-08-03 | 2012-09-18 | David Castillejos | Method and intra sclera implant for treatment of glaucoma and presbyopia |
US7195774B2 (en) | 2001-08-29 | 2007-03-27 | Carvalho Ricardo Azevedo Ponte | Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
-
2002
- 2002-08-28 US US10/231,767 patent/US7195774B2/en not_active Expired - Lifetime
- 2002-08-28 ES ES02759478T patent/ES2393101T3/es not_active Expired - Lifetime
- 2002-08-28 RU RU2004109574/14A patent/RU2311892C2/ru not_active IP Right Cessation
- 2002-08-28 CA CA2456025A patent/CA2456025C/en not_active Expired - Lifetime
- 2002-08-28 AU AU2002324811A patent/AU2002324811B2/en not_active Ceased
- 2002-08-28 BR BR0205990-8A patent/BR0205990A/pt not_active Application Discontinuation
- 2002-08-28 WO PCT/US2002/027434 patent/WO2003020172A1/en active Application Filing
- 2002-08-28 EP EP02759478A patent/EP1420716B1/de not_active Expired - Lifetime
- 2002-08-28 CN CN028215613A patent/CN1578647B/zh not_active Expired - Fee Related
- 2002-08-28 PT PT02759478T patent/PT1420716E/pt unknown
- 2002-08-28 JP JP2003524486A patent/JP2005501602A/ja active Pending
-
2003
- 2003-05-28 ZA ZA200304159A patent/ZA200304159B/en unknown
-
2009
- 2009-08-03 JP JP2009180978A patent/JP4374077B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP4374077B2 (ja) | 2009-12-02 |
CA2456025A1 (en) | 2003-03-13 |
EP1420716B1 (de) | 2012-08-15 |
EP1420716A4 (de) | 2010-10-27 |
US7195774B2 (en) | 2007-03-27 |
EP1420716A1 (de) | 2004-05-26 |
BR0205990A (pt) | 2004-01-13 |
WO2003020172A1 (en) | 2003-03-13 |
JP2009254864A (ja) | 2009-11-05 |
AU2002324811B2 (en) | 2008-07-24 |
CN1578647A (zh) | 2005-02-09 |
ES2393101T3 (es) | 2012-12-18 |
PT1420716E (pt) | 2012-11-21 |
JP2005501602A (ja) | 2005-01-20 |
CN1578647B (zh) | 2010-04-07 |
US20030064088A1 (en) | 2003-04-03 |
RU2004109574A (ru) | 2005-04-10 |
CA2456025C (en) | 2011-11-22 |
RU2311892C2 (ru) | 2007-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2456025C (en) | An implantable and sealable system for unidirectional delivery of therapeutic agents to tissues | |
AU2002324811A1 (en) | An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues | |
US7749528B2 (en) | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues | |
US6986900B2 (en) | Ophthalmic drug delivery device | |
US7094226B2 (en) | Ophthalmic drug delivery device | |
JP4685311B2 (ja) | 眼薬送出装置 | |
JP5416048B2 (ja) | 眼内薬物送達のためのリザーバデバイス | |
ES2231781T3 (es) | Implantes oculares biocompatibles. | |
ES2231257T3 (es) | Dispositivo para la administracion de farmacos. | |
AU2002319606A1 (en) | Ophthalmic drug delivery device | |
AU2002319596A1 (en) | Ophthalmic drug delivery device | |
TWI323667B (en) | Implantable and sealable device for unidirectional delivery of therapeutic agents to tissues |